Philogen (PHIL) Aktievy
Philogen S.p.A. är ett bioteknikföretag som utvecklar läkemedel för onkologi och kroniska inflammatoriska sjukdomar. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 6/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 3/6 |
PHIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Philogen S.p.A. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €25.45 |
| 52 veckors högsta | €25.95 |
| 52 veckors lägsta | €19.56 |
| Beta | -0.015 |
| 1 månads förändring | 17.01% |
| 3 månaders förändring | 27.38% |
| 1 års förändring | 17.82% |
| 3 års förändring | 62.10% |
| 5 års förändring | 89.36% |
| Förändring sedan börsintroduktionen | 52.49% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 26
PHIL: Future Repricing Will Hinge On Lean Margins And Elevated P/E
Analysts have raised their price target on Philogen from €23.00 to about €27.67, citing updated fair value estimates, a slightly higher discount rate, and revised assumptions for revenue trends, profit margins, and future P/E levels. What’s in the News for Philogen No recent Philogen specific news items were identified in the provided sources.Uppdatering av berättelse • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.
Ny berättelse • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Recent updates
Uppdatering av berättelse • Jun 26
PHIL: Future Repricing Will Hinge On Lean Margins And Elevated P/E
Analysts have raised their price target on Philogen from €23.00 to about €27.67, citing updated fair value estimates, a slightly higher discount rate, and revised assumptions for revenue trends, profit margins, and future P/E levels. What’s in the News for Philogen No recent Philogen specific news items were identified in the provided sources.Uppdatering av berättelse • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.Ny berättelse • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Apr 06
PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.Uppdatering av berättelse • Mar 23
PHIL: 2026 Board Schedule Will Support Confidence In Future Repricing Potential
Analysts have kept their price target for Philogen steady at €26.0, indicating only minimal tweaks in the discount rate and forward P/E assumptions, while leaving profit margin expectations unchanged. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company event) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on the first quarter of 2026 (company event) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company event) Board meeting scheduled for November 12, 2026, to approve a press release containing a quarterly report with selected information on the third quarter of 2026 (company event) Valuation Changes Fair Value: kept steady at €26.0 per share, with no change in the central valuation level.Uppdatering av berättelse • Mar 08
PHIL: 2026 Board Timetable Will Support Confidence In Future Upside
Analysts have left their fair value estimate for Philogen steady at €26.0. They point to only minor tweaks in the discount rate and assumed future P/E that reflect updated risk and earnings assumptions rather than a shift in their overall view. What's in the News Board meeting scheduled for March 27, 2026 to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026 to approve the press release that will contain the quarterly report with selected information on first quarter 2026 performance (company filing) Board meeting planned for September 23, 2026 to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting on November 12, 2026 to approve the press release that will contain the quarterly report with selected information on third quarter 2026 performance (company filing) Valuation Changes Fair Value: Kept steady at €26.0 per share, with no change in the headline estimate.Uppdatering av berättelse • Feb 21
PHIL: 2026 Board Milestones Will Support Confidence In Future Upside
Analysts have made only a marginal adjustment to their valuation framework for Philogen, keeping the fair value anchor steady at around €26 while fine tuning inputs such as the discount rate, revenue growth assumptions and future P/E to reflect updated risk and earnings expectations. What's in the News Board meeting scheduled for March 27, 2026, to approve the draft financial statements and the 2025 consolidated financial statements (company event calendar).Uppdatering av berättelse • Feb 06
PHIL: Upcoming Trial Readouts And 2026 Milestones Will Support Upside Potential
Narrative Update on Philogen Analysts now set their price target for Philogen at €26.00, broadly in line with the prior €26 level. This reflects modestly lower discount rate and future P/E assumptions that fine tune their view of the company’s risk and valuation profile.Uppdatering av berättelse • Jan 23
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have modestly lifted their price target for Philogen to €26.00 per share, reflecting small tweaks to their discount rate and long term P/E assumptions, while keeping fair value otherwise unchanged. What's in the News Philogen provided an update on the FIBROSARC Phase III trial, which tests fibromun plus doxorubicin versus doxorubicin alone as first line treatment for advanced or metastatic soft tissue sarcoma.Uppdatering av berättelse • Jan 08
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have adjusted their price target for Philogen to €26.00. The change reflects slightly higher perceived risk through a modestly higher discount rate and a broadly unchanged outlook for margins and future P/E assumptions.Uppdatering av berättelse • Dec 19
PHIL: Future Sarcoma Trial Progress Will Support Upside From Current Levels
Analysts have nudged their price target on Philogen slightly higher to €26.00. This reflects unchanged assumptions on fair value, discount rate, and long term profitability, while acknowledging the resilience of the company’s margin outlook despite subdued growth expectations.Uppdatering av berättelse • Dec 05
PHIL: Future Trial Milestones And Buyback Activity Will Support Fair Value
Analysts have modestly raised their price target on Philogen to €26.00 per share, reflecting improved expectations for long term profit margins and valuation multiples, despite slightly lower near term revenue growth forecasts. What's in the News Philogen reported updated data from its FIBROSARC Phase III trial of fibromun plus doxorubicin in advanced or metastatic soft tissue sarcoma, with primary endpoint progression free survival and plans to present full results at scientific conferences and in a peer reviewed journal in 2026 (Key Developments).Uppdatering av berättelse • Nov 20
PHIL: Share Buyback and Stable Financials Will Support Current Fair Value
Narrative Update on Philogen Analysts have maintained their price target for Philogen at €26.00. They cite continued confidence in the company’s outlook despite only minor adjustments to valuation inputs.Uppdatering av berättelse • Nov 05
PHIL: Share Buyback and Stable Metrics Expected to Sustain Fair Value
Narrative Update: Philogen Price Target Revision Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.Uppdatering av berättelse • Oct 22
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Analysts have maintained their price target for Philogen at €26.00 per share, citing stable expectations for key financial metrics and future performance. What's in the News Philogen completed the repurchase of 29,448 shares, representing 0.07% of total shares, for €0.66 million under the buyback program announced on May 12, 2025 (Key Developments).Uppdatering av berättelse • Oct 08
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Analysts have lowered their price target for Philogen from $28.00 to $26.00. This decision is based on revisions in revenue growth projections and a significant reduction in estimated profit margins.Analysartikel • Oct 04
Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Despite posting strong earnings, Philogen S.p.A.'s ( BIT:PHIL ) stock didn't move much over the last week. We decided...Ny berättelse • Aug 20
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Analysartikel • Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Philogen S.p.A. ( BIT:PHIL ) shareholders will have a reason to smile today, with the analysts making substantial...Analysartikel • Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Philogen S.p.A. ( BIT:PHIL ) last week reported its latest yearly results, which makes it a good time for investors to...Analysartikel • Feb 24
What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 25.1x Philogen S.p.A. ( BIT:PHIL ) is a stock to avoid...Analysartikel • Jun 03
Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Aktieägarnas avkastning
| PHIL | IT Biotechs | IT Marknad | |
|---|---|---|---|
| 7D | 4.1% | -1.6% | -0.3% |
| 1Y | 17.8% | 42.0% | 23.7% |
Avkastning vs industri: PHIL presterade sämre än Italian Biotechs branschen som gav 42 % under det senaste året.
Avkastning vs Marknaden: PHIL presterade sämre än Italian marknaden som gav 23.7 % under det senaste året.
Prisvolatilitet
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in IT Market | 8.1% |
| 10% least volatile stocks in IT Market | 3.0% |
Stabil aktiekurs: PHIL har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Italian.
Volatilitet över tid: PHIL s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1996 | 214 | Dario Neri | www.philogen.com |
Philogen S.p.A. är ett bioteknikföretag som utvecklar läkemedel för onkologi och kroniska inflammatoriska sjukdomar. Företaget utvecklar Nidlegy, en kombination av immunocytokinerna L19IL2 och L19TNF för intralesionell behandling av lokoregionalt melanom och icke-melanom hudcancer; Fibromun, en human immunmodulerande produkt bestående av L19-antikroppen och TNF för behandling av mjukdelssarkom, leiomyosarkom och gliom; och Darleukin (L19IL2), en human immunstimulerande produkt bestående av den humana L19-antikroppen fusionerad med den humana cytokinen interleukin-2 (IL2), som befinner sig i klinisk fas II-studie för behandling av icke-småcellig lungcancer. Bolaget utvecklar också Dodekin, en human immunstimulerande produkt som består av en antikropp som riktar sig mot kärl och som är sammansmält med interleukin-12.
Philogen S.p.A. Sammanfattning av grunderna
| PHIL grundläggande statistik | |
|---|---|
| Börsvärde | €1.03b |
| Vinst(TTM) | €229.68m |
| Intäkter(TTM) | €319.73m |
4.5x
P/E-förhållande3.2x
P/S-förhållandeÄr PHIL övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PHIL resultaträkning (TTM) | |
|---|---|
| Intäkter | €319.73m |
| Kostnad för intäkter | €39.57m |
| Bruttovinst | €280.16m |
| Övriga kostnader | €50.49m |
| Intäkter | €229.68m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Sep 23, 2026
| Vinst per aktie (EPS) | 5.70 |
| Bruttomarginal | 87.62% |
| Nettovinstmarginal | 71.83% |
| Skuld/egenkapitalförhållande | 0.01% |
Hur har PHIL utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
2.8%
Aktuell utdelningsavkastning12%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/09 07:35 |
| Aktiekurs vid dagens slut | 2026/07/09 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Philogen S.p.A. bevakas av 4 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |